1536P - Multicenter institutional experience of surgically resected thymic epithelial tumors (TETs): an observational report on behalf of F.O.N.I.C.A.P. (Fo...

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Thymoma and Thymic Cancer
Surgical Oncology
Radiation Oncology
Presenter Giovenzio Genestreti
Authors G. Genestreti1, M.A. Burgio1, L. Ampollini2, S. Sanna3, M. Monti1, A. Santo4, M. Mezzetti5, G. Gavelli6, A. Verlicchi7, R. Buosi8
  • 1Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, 47014 - Meldola (FC)/IT
  • 2Department Of Thoracic Surgery, University Hospital, Parma, Italy, Parma/IT
  • 3Department Of Thoracic Surgery, Morgagni-Pierantoni Hospital, Forlì, Italy, Forlì/IT
  • 4Department Of Medical Oncology, University Hospital, Verona, Italy, Verona/IT
  • 5Department Of Thoracic Surgery, San Carlo Clinic, Milan, Italy, Milan/IT
  • 6Department Of Radiology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC)/IT
  • 7Dipartimento Di Oncologia/ematologia, Ospedale Civile di Ravenna - S.ta Maria delle Croci, IT-48121 - Ravenna/IT
  • 8Department Of Clinical Oncology, Civil Hospital, Novara, Italy, Novara/IT



thymic epithelial tumors (TETs) are a rare neoplasms. Due to their rarity, large-scale prospective trials are lacking. The present retrospective multicenter analysis aimed to evaluate clinical outcome and clinical-pathological features of TETs after complete surgical resection and adjuvant treatments (Adj) such as chemotherapy (CHT) or radiotherapy (RT).

Patients and methods

Patients who underwent a complete surgical resections for TETs between 2000 and 2007 were reviewed. WHO histological classification criteria and Masaoka staging system were used. Adj were: anthracycline- and platin-based CHT, RT on irradiation fields covering the primary tumor bed. Overall survival (OS) was calculated from the date of diagnosis until patient death or last follow-up visit. Disease free-survival (DFS) was defined as the interval between surgery and date of first documentation of recurrence. OS, DFS and 95% Confidence Interval (95% CI) were estimated by Kaplan-Meier method.


62 patients were analyzed: 30 patients (48%) male and 32 (52%) female. Median age was 60 years (range: 33 - 86). At the beginning of their cancer history 20 (32%) patients had myasthenia. Clinical staging showed: 31 (50%) stage I disease, 19 (30%) stage II, 5 (8%) stage III, 2 (4%) stage IVa, 5 (8%) stage IVb. Histologies were: 11 (19%) A tumor type, 18 (29%) AB type, 7 (12%) B1 type, 11 (17%) B2 type, 11 (17%) B3 type and 3 (6%) C type. Pathological staging were: 30 (48%) stage I, 22 (35%) stage II, 3 (6%) stage III, 2 (3%) stage IVa, 5 (8%) stage IVb. 3 (5%) patients received Adj-CHT and 16 (26%) Adj-RT. Median follow-up was 71 months (range 1-145), DFS and OS are the following:

% DFS (95% CI) % OS (95% CI)
Events 48 mo 60 o0 72 mo Events 48 mo 60 mo 72 mo
9 89 (80-97) 89 (80-97) 86 (76-96) 7 97 (92-100) 95 (88-100) 92 (85-100)

mo, months.


TETs are rare and indolent tumors. Surgery offers good results which can be further improved by Adj such as CHT and/or RT. Supported by GIPO.


All authors have declared no conflicts of interest.